ADMA — ADMA Biologics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.58bn
- $1.66bn
- $258.22m
- 74
- 11
- 97
- 63
Annual cashflow statement for ADMA Biologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -48.3 | -75.7 | -71.6 | -65.9 | -28.2 |
| Depreciation | |||||
| Non-Cash Items | 2.33 | 3.58 | 5.46 | 17.6 | 38.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -33.5 | -33.8 | -51.7 | -18.3 | -10.1 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -76.2 | -102 | -112 | -59.5 | 8.8 |
| Capital Expenditures | -3.81 | -12.7 | -13.5 | -13.9 | -4.98 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | 0.002 | 0 | — | — |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -3.81 | -12.7 | -13.5 | -13.9 | -4.98 |
| Financing Cash Flow Items | -10.9 | -0.83 | -0.062 | -7.68 | -16.5 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 80 | 144 | 121 | 109 | -39 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.003 | 29.2 | -4.83 | 35.4 | -35.2 |